Key result
Angiographic microvascular resistance index >250 is linked to ~94% higher MACE risk.
Why the study?
Coronary microcirculatory resistance indices predict patient prognosis, and angiography-based methods offer simplicity and cost-effectiveness, but the prognostic value of the novel angiographic microvascular resistance (AMR) index in TAVR patients required confirmation.
Does an angiographic microvascular resistance (AMR) > 250 predict major adverse cardiovascular events in patients undergoing transcatheter aortic valve replacement?
Cohort (n=335)
No
Does an angiographic microvascular resistance (AMR) > 250 predict major adverse cardiovascular events in patients undergoing transcatheter aortic valve replacement?
An angiographic microvascular resistance (AMR) > 250 is an independent predictor of adverse clinical outcomes after transcatheter aortic valve replacement.
Background The coronary microcirculatory resistance index plays a crucial role in predicting patient prognosis. Coronary angiography‐based methods for assessing coronary microcirculatory function offer advantages such as simplicity and cost‐effectiveness. This study aimed to confirm the prognostic value of a novel angiographic microvascular resistance (AMR) index in patients undergoing transcatheter aortic valve replacement. Methods and Results We prospectively included 335 patients with severe aortic stenosis who underwent transcatheter aortic valve replacement at Fuwai Hospital. The AMR was calculated based on coronary angiography performed before prosthetic valve implantation. Patients were divided into 2 groups based on an AMR cutoff value of 250: AMR ≤250 and AMR >250. The primary end point was major adverse cardiovascular events, defined as a composite of all‐cause mortality, readmission for heart failure, and myocardial infarction. At a median follow‐up of 40 months (interquartile range [IQR], 25–50), AMR was significantly higher in patients who experienced the primary end point (257 [IQR, 186–299] versus 226 [IQR, 177–264]; P <0.001), identifying it as an independent risk factor for major adverse cardiovascular events, all‐cause mortality, and new‐onset atrial fibrillation. Kaplan‐Meier analysis indicated that patients with AMR >250 had significantly lower event‐free survival rates for major adverse cardiovascular events (62.9% versus 75.1%; hazard ratio, 1.94 [95% CI, 1.34–2.81]; log‐rank P <0.001), mainly driven by all‐cause death (75.7% versus 83.4%, log‐rank P =0.018). Subgroup analyses supported these findings for major adverse cardiovascular events. Conclusions AMR is an independent predictor of adverse clinical outcomes after transcatheter aortic valve replacement. An AMR >250 can be used as a novel indicator for long‐term prognostic management.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2025) conducted a cohort in Severe aortic stenosis undergoing transcatheter aortic valve replacement (n=335). Angiographic microvascular resistance (AMR) >250 vs. AMR ≤250 was evaluated on Major adverse cardiovascular events (composite of all-cause mortality, readmission for heart failure, and myocardial infarction) (HR 1.94, 95% CI 1.34-2.81, p=<0.001). An angiographic microvascular resistance index >250 was associated with significantly lower event-free survival for major adverse cardiovascular events compared to ≤250 (62.9% vs 75.1%; HR 1.94).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: